Double-Gradient–Denaturing-Gradient Gel Electrophoresis for Mutation Screening of the BCR-ABL Tyrosine Kinase Domain in Chronic Myeloid Leukemia Patients-Reference-Cited by-同舟云学术

Double-Gradient–Denaturing-Gradient Gel Electrophoresis for Mutation Screening of the BCR-ABL Tyrosine Kinase Domain in Chronic Myeloid Leukemia Patients

Published:2005-07-01 Issue:7 Volume:51 Page:1263-1266
ISSN:0009-9147
Container-title:Clinical Chemistry
language:en
Short-container-title:

Author:

Sorel Nathalie¹,Chazelas Florence¹,Brizard André,Chomel Jean-Claude

Affiliation:

1. Laboratoire d’Hématologie et EA 3805, CHU de Poitiers, France

Publisher

Oxford University Press (OUP)

Subject

Biochemistry, medical,Clinical Biochemistry

Link

http://academic.oup.com/clinchem/article-pdf/51/7/1263/32683607/clinchem1263.pdf

Reference16 articles.

1. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature1985;315:550-554.

2. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res1996;56:100-104.

3. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia [Review]. J Clin Invest2000;105:3-7.

4. Dorey K, Engen JR, Kretzschmar J, Wilm M, Neubauer G, Schindler T, et al. Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase. Oncogene2001;20:8075-8084.

5. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med2002;346:645-652.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell–derived hematopoiesis model;Experimental Hematology;2013-04

2. Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis;Pharmacogenomics;2012-08

3. Chronic Myeloid Leukemia: Clinical Impact of BCR-ABL1 Mutations and Other Lesions Associated With Disease Progression;Seminars in Oncology;2012-02

4. Sensitive Detection of BCR-ABL1 Mutations in Patients With Chronic Myeloid Leukemia After Imatinib Resistance Is Predictive of Outcome During Subsequent Therapy;Journal of Clinical Oncology;2011-11-10

5. Molecular methods in diagnosis and monitoring of haematological malignancies;Pathology;2011-10